These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7929024)

  • 1. Treatment of refractory OCD with the dopamine agonist bromocriptine.
    Ceccherini-Nelli A; Guazzelli M
    J Clin Psychiatry; 1994 Sep; 55(9):415-6. PubMed ID: 7929024
    [No Abstract]   [Full Text] [Related]  

  • 2. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis.
    McDougle CJ; Goodman WK; Leckman JF; Price LH
    Psychiatr Clin North Am; 1993 Dec; 16(4):749-66. PubMed ID: 8309811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
    Korff S; Harvey BH
    Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
    Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine:dopamine-receptor agonist.
    Dipalma JR
    Am Fam Physician; 1976 Dec; 14(6):88-9. PubMed ID: 1036662
    [No Abstract]   [Full Text] [Related]  

  • 7. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric MRI assessment of brain regions in patients with refractory obsessive-compulsive disorder.
    Atmaca M; Yildirim B H; Ozdemir B H; Aydin B A; Tezcan A E; Ozler A S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1051-7. PubMed ID: 16687198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment.
    Saxena S; Maidment KM; Vapnik T; Golden G; Rishwain T; Rosen RM; Tarlow G; Bystritsky A
    J Clin Psychiatry; 2002 Jan; 63(1):21-7. PubMed ID: 11838621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroacupuncture for refractory obsessive-compulsive disorder: a pilot waitlist-controlled trial.
    Zhang ZJ; Wang XY; Tan QR; Jin GX; Yao SM
    J Nerv Ment Dis; 2009 Aug; 197(8):619-22. PubMed ID: 19684500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome.
    Perugi G; Toni C; Frare F; Travierso MC; Hantouche E; Akiskal HS
    J Clin Psychiatry; 2002 Dec; 63(12):1129-34. PubMed ID: 12523872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of intensive residential treatment (IRT) for severe, refractory obsessive-compulsive disorder.
    Stewart SE; Stack DE; Farrell C; Pauls DL; Jenike MA
    J Psychiatr Res; 2005 Nov; 39(6):603-9. PubMed ID: 16157162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].
    Ohmoto T; Miyamoto T; Baba Y
    No To Shinkei; 1977 Jul; 29(7):?31-40. PubMed ID: 409419
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(4):677-82. PubMed ID: 8993091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome predictors for severe obsessive-compulsive patients in intensive residential treatment.
    Stewart SE; Yen CH; Stack DE; Jenike MA
    J Psychiatr Res; 2006 Sep; 40(6):511-9. PubMed ID: 16229857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine treatment of obsessive-compulsive disorder.
    Lundberg S; Carlsson A; Norfeldt P; Carlsson ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1195-9. PubMed ID: 15610934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.
    Khullar A; Chue P; Tibbo P
    J Psychiatry Neurosci; 2001 Jan; 26(1):55-9. PubMed ID: 11212595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Delgado PL; Price LH
    Am J Psychiatry; 1989 Oct; 146(10):1350-1. PubMed ID: 2782483
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
    Rabinowitz I; Baruch Y; Barak Y
    Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.